117 related articles for article (PubMed ID: 11996793)
1. Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene.
Dubourg C; Toutain B; Hélias C; Henry C; Lessard M; Le Gall JY; Le Treut A; Guenet L
Cancer Genet Cytogenet; 2002 Apr; 134(1):33-7. PubMed ID: 11996793
[TBL] [Abstract][Full Text] [Related]
2. Eukaryotic translation termination factor gene (ETF1/eRF1) maps at D5S500 in a commonly deleted region of chromosome 5q31 in malignant myeloid diseases.
Guenet L; Henry C; Toutain B; Dubourg C; Le Gall JY; David V; Le Treut A
Cytogenet Cell Genet; 2000; 88(1-2):82-6. PubMed ID: 10773672
[TBL] [Abstract][Full Text] [Related]
3. Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and not mutated in the retained allele in human leukemia cell line HL60.
Zavadil J; Brezinová J; Svoboda P; Zemanová Z; Michalová K
Leukemia; 1997 Aug; 11(8):1187-92. PubMed ID: 9264367
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
Le Beau MM; Espinosa R; Neuman WL; Stock W; Roulston D; Larson RA; Keinanen M; Westbrook CA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5484-8. PubMed ID: 8516290
[TBL] [Abstract][Full Text] [Related]
6. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.
Lezon-Geyda K; Najfeld V; Johnson EM
Leukemia; 2001 Jun; 15(6):954-62. PubMed ID: 11417483
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the 5q- chromosome.
Nagarajan L
Leuk Lymphoma; 1995 May; 17(5-6):361-6. PubMed ID: 7549826
[TBL] [Abstract][Full Text] [Related]
8. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
[TBL] [Abstract][Full Text] [Related]
9. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31.
Horrigan SK; Arbieva ZH; Xie HY; Kravarusic J; Fulton NC; Naik H; Le TT; Westbrook CA
Blood; 2000 Apr; 95(7):2372-7. PubMed ID: 10733509
[TBL] [Abstract][Full Text] [Related]
10. Localization of SMAD5 and its evaluation as a candidate myeloid tumor suppressor.
Hejlik DP; Kottickal LV; Liang H; Fairman J; Davis T; Janecki T; Sexton D; Perry W; Tavtigian SV; Teng DH; Nagarajan L
Cancer Res; 1997 Sep; 57(17):3779-83. PubMed ID: 9288787
[TBL] [Abstract][Full Text] [Related]
11. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).
Lai F; Godley LA; Joslin J; Fernald AA; Liu J; Espinosa R; Zhao N; Pamintuan L; Till BG; Larson RA; Qian Z; Le Beau MM
Genomics; 2001 Jan; 71(2):235-45. PubMed ID: 11161817
[TBL] [Abstract][Full Text] [Related]
12. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia.
Willman CL; Sever CE; Pallavicini MG; Harada H; Tanaka N; Slovak ML; Yamamoto H; Harada K; Meeker TC; List AF
Science; 1993 Feb; 259(5097):968-71. PubMed ID: 8438156
[TBL] [Abstract][Full Text] [Related]
13. 5q-: pathogenetic importance of the common deleted region and clinical consequences of the entire deleted segment.
Pedersen B
Anticancer Res; 1993; 13(5C):1913-6. PubMed ID: 8267400
[TBL] [Abstract][Full Text] [Related]
14. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
[TBL] [Abstract][Full Text] [Related]
15. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
MacKinnon RN; Kannourakis G; Wall M; Campbell LJ
Cancer Genet; 2011 Apr; 204(4):187-94. PubMed ID: 21536236
[TBL] [Abstract][Full Text] [Related]
16. Rare tetraploidy with large 5q deletion in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).
Jarosova M; Nedomova R; Hubacek J; Holzerova M; Mickova P; Katrincsakova B; Pikalova Z; Papajik T; Indrak K
Leuk Res; 2012 Apr; 36(4):e68-70. PubMed ID: 22284693
[No Abstract] [Full Text] [Related]
17. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
18. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
19. Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7.
Ferrari T; Weber B; Pils S; Harbott J; Borkhardt A
Ann Hematol; 2001 Feb; 80(2):72-3. PubMed ID: 11261327
[TBL] [Abstract][Full Text] [Related]
20. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ.
Soenen V; Preudhomme C; Roumier C; Daudignon A; Laï JL; Fenaux P
Blood; 1998 Feb; 91(3):1008-15. PubMed ID: 9446663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
